Verdict: Shifa International Hospitals Limited delivered another year of revenue growth in FY2026, but the group result became more complicated as expansion accelerated. Consolidated revenue rose 12.0% to Rs31.32 billion and profit for the year increased 10.7% to Rs2.47 billion. The quality of growth weakened late in the year: an arithmetic Q4 bridge shows revenue up about 21.7% year on year, while profit for the quarter fell about 21.6% because operating costs, finance costs and expected credit losses rose faster. At the same time, the group invested heavily in new capacity, including the Faisalabad expansion, and operating cash flow fell despite higher earnings. The central FY2026 story is therefore not simply “higher profit”; it is a transition from a mature Islamabad-led earnings base toward a larger hospital network, with near-term pressure on cash conversion, liquidity and subsidiary economics.
Results at a glance
Company Name: Shifa International Hospitals Limited
Ticker: SHFA
Reporting period: Year ended June 30, 2026. The official PSX result package released on September 14, 2026 contains both unconsolidated and consolidated annual result statements. This article uses the consolidated statements as the primary reporting basis because they capture the group. The result packet states that the Annual Report will be transmitted later and does not contain the independent auditor’s report; accordingly, no audit opinion is inferred here. The nine-month consolidated statements used for the Q4 arithmetic bridge were explicitly unaudited.
Alpha QoQ Score: 10.64
TTM Performance Score: 58.39
3Y Business Perf Score: 94.48
Sector Leadership Score: 48.0116
These four scores are AlphaGen model outputs, not company-reported figures.
- Consolidated revenue rose 12.0% to Rs31.32 billion from Rs27.97 billion. Profit attributable to equity holders increased 11.7% to Rs2.52 billion; total group profit rose 10.7% to Rs2.47 billion.
- Operating costs increased 12.8% to Rs26.87 billion, slightly faster than revenue. Finance costs rose 17.8% to Rs407.1 million and expected credit losses doubled to Rs282.2 million.
- Net operating cash flow declined 9.1% to Rs3.70 billion even though profit increased. Cash taxes rose sharply and working capital moved from a source of cash to a small use of cash.
- Purchases of property, plant and equipment jumped to Rs4.53 billion from Rs1.58 billion. Consolidated property, plant and equipment rose 31.7% to Rs19.74 billion.
- The board recommended a final cash dividend of Rs5 per share, subject to shareholder approval.
What improved
The first improvement is scale. Consolidated revenue increased by about Rs3.35 billion, or 12.0%, during FY2026. That growth was stronger than the parent-company increase: standalone revenue rose 8.3% to Rs30.28 billion. The difference matters because the group is no longer just the established parent hospital operation. Subsidiaries and new facilities are becoming more visible in the consolidated base, and that makes consolidated figures the more useful lens for assessing the economic footprint of Shifa’s expansion.
Other income also rose 28.3% to Rs491.6 million, providing an additional earnings contribution. Profit before levies and income tax increased 4.5% to Rs4.25 billion, while the income-tax expense fell about 4.7% to Rs1.74 billion. Those below-the-line movements helped group profit rise despite heavier financing and credit-loss charges.
The balance sheet also shows a materially larger operating platform. Total assets increased 18.4% to Rs29.61 billion and consolidated property, plant and equipment rose 31.7% to Rs19.74 billion. That asset growth is consistent with a year in which the group moved from development into commissioning of additional hospital capacity rather than merely extracting more revenue from the existing base.
The most important operating development was the Faisalabad expansion. Shifa disclosed that Shifa National Hospital Faisalabad commenced full-fledged operations under Phase I in June 2026. The company’s current Faisalabad site describes a tertiary-care facility with more than 25 clinical specialties, more than 50 clinical consultants, emergency services and critical-care capability. Because full operations began only near the fiscal-year end, it is reasonable to infer that FY2026 captured only a limited period of mature revenue contribution from this new capacity; that inference should not be confused with a company-provided revenue split.
What weakened / needs attention
Revenue growth did not produce operating leverage at the group level. Consolidated operating costs increased 12.8%, slightly faster than the 12.0% increase in revenue. In a hospital business, this can reflect the cost of staffing, utilities, clinical supplies and commissioning capacity ahead of mature utilization, but the FY2026 result packet does not provide a cost-by-driver bridge. The safest conclusion is therefore narrower: cost growth marginally outpaced revenue growth, so the incremental sales did not translate into a stronger operating-cost ratio.
Finance costs rose 17.8% to Rs407.1 million. The balance sheet helps explain why financing remains relevant: long-term financing increased to roughly Rs1.66 billion from Rs0.85 billion, lease liabilities rose to about Rs0.95 billion from Rs0.51 billion, and the current portion of long-term obligations increased to about Rs0.56 billion. Taken together, these disclosed financing obligations rose to roughly Rs3.18 billion from Rs1.81 billion. That is consistent with an asset-heavy expansion phase, although the result package does not allocate borrowing to individual projects.
Expected credit losses are another important drag. The full-year charge doubled to Rs282.2 million from Rs141.0 million. This is not a trivial accounting footnote: trade receivables increased 30.9% to Rs1.91 billion, far faster than revenue. Higher receivables can accompany a larger institutional and insured-patient base, but the filing does not disclose payer mix or ageing in the result packet. Until the annual notes are available, the key fact is that credit exposure expanded materially and the loss allowance moved in the same direction.
The final quarter tells a different story from the full year
The annual numbers are stronger than the exit-quarter economics. Using the official FY2026 consolidated result minus the official unaudited nine-month consolidated result produces an arithmetic Q4 bridge. This is not a separately reported quarter and should not be treated as one for audit or disclosure purposes; it is simply a reconciliation tool.
On that basis, derived Q4 revenue was about Rs8.64 billion versus Rs7.10 billion a year earlier, an increase of 21.7%. Yet derived Q4 profit was only about Rs343 million versus Rs438 million, down 21.6%. The gap is economically important: the group exited the year with faster revenue growth but weaker profit conversion.
The bridge shows why. Derived Q4 operating costs rose about 24.5% year on year, faster than revenue. Finance costs rose about 41.2% to roughly Rs122 million. Expected credit losses were about Rs143 million in the derived quarter, compared with an implied reversal of roughly Rs13 million in the prior-year residual. Other income rose, but not enough to offset those pressures. Profit before levies and income tax in the derived Q4 bridge fell about 18.8%.
This does not prove that the new Faisalabad facility caused the Q4 margin pressure. The timing makes ramp-up costs a plausible factor, but the public result package does not provide a facility-level profit-and-loss statement. The defensible conclusion is that the year-end growth mix became less profitable: costs, financing and credit-loss expense absorbed a larger share of the incremental revenue.
Parent strength versus group economics
The standalone and consolidated results reveal another useful tension. Parent-company revenue rose 8.3% and standalone PAT increased 19.9% to Rs2.79 billion. At group level, revenue grew faster at 12.0%, but total profit rose only 10.7% to Rs2.47 billion. In FY2026 the consolidated group generated about Rs1.03 billion more revenue than the standalone parent, yet group profit was about Rs322 million lower than standalone PAT.
That gap should not be mechanically labelled a subsidiary loss because consolidation includes inter-company eliminations, non-controlling interests and associate effects. Still, it shows that the incremental group footprint is not yet producing the same profit conversion as the parent. This is exactly what investors should expect to scrutinize during an expansion cycle: whether new hospitals and subsidiaries move from asset build-out and commissioning costs toward sustainable utilization and earnings.
The consolidated statement also recorded a small Rs0.7 million share of loss from an associate versus a Rs16.1 million profit in FY2025. Non-controlling interests absorbed a Rs51.1 million loss versus a Rs26.1 million loss a year earlier. Those items are small relative to group earnings, but they reinforce the point that consolidated economics differ from the mature parent operation.
Cash conversion weakened despite higher earnings
Net cash generated from operating activities fell 9.1% to Rs3.70 billion from Rs4.08 billion. Before working-capital movements, operating cash flow improved to Rs6.63 billion from Rs6.07 billion, which is constructive. The deterioration came later in the bridge: working capital was a Rs9 million use of cash compared with a Rs263 million source in FY2025, and cash income-tax payments climbed to Rs2.27 billion from Rs1.59 billion.
Receivables were the biggest working-capital pressure, absorbing about Rs648 million of cash during FY2026. Inventory also increased, while payables provided a partial offset. The result is a business that remained cash-generative but converted a smaller share of its higher accounting earnings into operating cash.
Investment spending was much heavier. Property, plant and equipment additions rose 186.7% to Rs4.53 billion, exceeding the entire Rs3.70 billion of operating cash generated after tax and finance costs. The group also spent on long-term investments and other assets. Financing therefore had to play a larger role, and cash and cash equivalents ended the year at Rs2.78 billion, down 26.0% from Rs3.76 billion.
Liquidity consequently became tighter. Current assets declined 2.2% while current liabilities rose 25.7%, reducing the consolidated current ratio to about 1.16 times from roughly 1.50 times. This is not a solvency conclusion, but it is a clear shift in short-term balance-sheet flexibility. The next cycle needs to show that the new asset base can generate enough incremental operating cash to rebuild that cushion.
Recurring versus exceptional and non-cash items
The recurring core is the hospital revenue base and the operating cost required to serve it. FY2026 continued the multi-year expansion in Shifa’s top line, and the new Faisalabad facility creates additional capacity for future revenue. The weak point is that the latest quarter’s cost growth exceeded its revenue growth, so the next result must establish whether that was a temporary commissioning effect or a more persistent cost issue.
Several items should be separated from recurring operating earnings. The group recognized a Rs691.1 million surplus on revaluation of land in other comprehensive income; this increased comprehensive income but did not flow through profit for the year. The statement of changes in equity also records effects from the group’s scheme of arrangement and merger activity. Those are capital-structure and accounting events, not healthcare-service revenue.
The corporate structure is still evolving. In October 2025 the board approved a scheme to merge Shifa Medical Center Islamabad into the listed parent, citing simplification of structure and elimination of inter-company layers. After the FY2026 reporting date, the Islamabad High Court sanctioned that scheme in July 2026. Because the court approval occurred after June 30, it should be treated as a post-period development rather than an FY2026 earnings driver. The economic question for future periods is whether integration lowers duplicated costs and improves asset utilization as intended.
What changed versus the historical pattern
Shifa entered FY2026 with a stronger earnings base than several years earlier. Official PSX standardized parent-company figures show revenue rising from about Rs19.72 billion in FY2023 to Rs23.56 billion in FY2024, Rs27.97 billion in FY2025 and Rs30.28 billion in FY2026, while standalone PAT increased from Rs1.18 billion to Rs1.36 billion, Rs2.33 billion and Rs2.79 billion over the same sequence. The direction is clear: the established parent operation has scaled materially.
FY2026 changes the nature of the story because balance-sheet expansion is now as important as income-statement growth. A larger hospital network means more fixed assets, start-up costs, receivables, financing and execution risk before new capacity reaches mature utilization. The historical pattern of steady parent growth is therefore no longer sufficient by itself to judge the group; consolidated return on new assets and cash conversion become more important.
What to monitor next
- Faisalabad utilization and economics: Phase I became fully operational near year-end. Revenue growth matters, but the more important question is whether utilization improves enough to absorb fixed clinical and staffing costs.
- Q4 cost pressure: the derived quarter showed operating costs growing faster than revenue, finance costs rising sharply and a much larger credit-loss charge. The next quarter will show whether that exit-rate pressure persists.
- Receivables and expected credit losses: trade debts rose about 31% and ECL doubled. Collection quality, payer mix and ageing disclosures will be important when the full annual report becomes available.
- Cash conversion and liquidity: operating cash flow fell, capex exceeded operating cash generation and the current ratio compressed. The expansion programme needs to begin producing incremental cash, not only incremental assets.
- Financing obligations: long-term financing and lease liabilities increased materially. Future finance cost will depend on both the funding mix and the pace at which new assets become productive.
- SMCI integration: the court-sanctioned merger is a post-period restructuring event. Future results should clarify the timing, accounting effects and any realized operating efficiencies.
- Group versus parent profitability: consolidated revenue is growing faster than standalone revenue, but group profit conversion is weaker. Closing that gap would be a key sign that expansion is maturing.
Bottom line
Shifa International’s FY2026 result shows a healthcare group in transition. Full-year consolidated revenue and profit both increased, the parent company remained strongly profitable, and the group brought meaningful new hospital capacity into operation. But the exit-quarter bridge was weaker than the annual headline: revenue accelerated while profit declined, with faster operating-cost growth, higher finance costs and a much larger expected-credit-loss charge. Cash conversion also softened as tax payments, receivables and a near-tripling of capital expenditure absorbed resources. The next result cycle should therefore be judged less on whether revenue keeps growing and more on whether new facilities improve group profit conversion, receivables normalize, operating cash flow recovers and the larger asset base begins to earn its keep.
Sources
- Pakistan Stock Exchange — Shifa International Hospitals Limited FY2026 official financial-results filing, including consolidated and standalone statements, cash flows and dividend announcement. Open FY2026 filing
- Pakistan Stock Exchange — Shifa International Hospitals Limited nine-month FY2026 official result filing, used for the Q4 arithmetic bridge and reporting-basis verification. Open 9M filing
- Pakistan Stock Exchange — SHFA company page, official announcement history and standardized historical financial series. Open PSX company page
- Pakistan Stock Exchange — October 27, 2025 material disclosure on the proposed merger of Shifa Medical Center Islamabad into Shifa International Hospitals Limited. Open merger disclosure
- Shifa International Hospitals — FY2025 Annual Report, used for previously disclosed group expansion, subsidiary structure and historical project context. Open FY2025 Annual Report
- Shifa International Hospitals — current Faisalabad hospital page, used to verify the operating facility and its disclosed clinical footprint. Open Faisalabad hospital page
- Mettis Global — June 15, 2026 report based on Shifa’s exchange disclosure confirming commencement of full-fledged Phase I operations at Shifa National Hospital Faisalabad. Open operating-update report
- Profit by Pakistan Today — July 17, 2026 report on Islamabad High Court sanction of the SMCI merger, used only for post-period restructuring context. Open post-period merger report